How pharma giant AbbVie holds leaders accountable for culture The pharmaceutical company is one of the honorees on the Fortune 100 Best Companies to Work For Europe list in 2025. Fortune · Oct 9, 2025
Why AbbVie and Johnson & Johnson Could Outperform Pfizer Pfizer stock is moving higher after being named part of the TrumpRx platform; but two other biopharma companies may offer better long-term growth potential MarketBeat · Oct 8, 2025
3 Exceptional Stocks to Build Long-Term Wealth Discover three standout growth stocks with strong long-term potential, spanning space, retail, and biotech industries, poised for sustained investor returns MarketBeat · Oct 6, 2025
AbbVie's Botox Shows Improvement In Movement Disorder Study AbbVie Inc. (NYSE:ABBV) on Monday shared topline results from the Phase 2 ELATE trial evaluating onabotulinumtoxinA (BOTOX) compared to placebo for upper limb essential tremor. Benzinga · Oct 6, 2025
AbbVie Stock Is Just What the Doctor Ordered AbbVie (ABBV) stands out after its Allergan acquisition thanks to a transformed portfolio and higher long-term growth prospects. ABBV is trading at fresh all-time highs. Shares have a 100% Barchart “Buy” opinion and are trading above key moving averages. Analyst and investor sentiment is positive, with most major firms rating... Barchart · Oct 1, 2025
3 Dividend Aristocrats Up 20%+ YTD With More Upside Ahead These 3 buy-rated Dividend Aristocrats are up 20%+ YTD, and offer reliable dividends with more growth potential ahead. Barchart · Sep 26, 2025
Novartis, AbbVie Face Legal Defeat Over 340B Contract Pharmacies A U.S. federal judge has rejected challenges by two pharmaceutical manufacturers seeking to block a Maine law that regulates the use of contract pharmacies under the federal 340B drug discount program. Benzinga · Sep 24, 2025
Should You Buy This Blue-Chip Dividend Stock at Record Highs? AbbVie shares have hit record highs after extending Rinvoq’s patent protection to 2037, boosting confidence in future earnings and dividend growth, with analysts seeing steady fundamentals and modest upside as the company’s immunology pipeline drives results. Barchart · Sep 17, 2025
The 5 Best Dividend Stocks to Buy for Steady Income in 2025 Here are five “set-and-forget” dividend stocks. Barchart · Sep 15, 2025
Why Is AbbVie Stock Trading Higher On Thursday? AbbVie Inc. (NYSE:ABBV) stock is trading higher on Thursday following an SEC filing that settled litigation with all generic manufacturers, which filed abbreviated new drug applications with the U.S. Food and Drug Administration for generic versions of upadacitinib tablets, marketed by the company as Rinvoq. Benzinga · Sep 11, 2025
Is AbbVie Stock Underperforming the S&P 500? AbbVie has underperformed the S&P 500 over the past year, but analysts are cautiously optimistic about the stock’s prospects. Barchart · Sep 1, 2025
These 2 Healthcare Stocks Are Even Better Bargain Buys Than UnitedHealth As the healthcare sector lags broader markets, AbbVie’s innovation in immunology and Johnson & Johnson’s MedTech expansion make these dividend giants standout bargains at below-market valuations Barchart · Aug 28, 2025
As the Market Rotates, This Healthcare ETF Is Leading the Way Health care saw some of the worst losses this year. But as the calendar turned to August, it's been leading the market higher. This ETF provides exposure. MarketBeat · Aug 26, 2025
AbbVie Strikes $1.2 Billion Agreement For Next-Gen Psychedelic Depression Treatment AbbVie Inc. (NYSE:ABBV) announced Monday that it will acquire Gilgamesh Pharmaceuticals Inc.’s lead investigational candidate for moderate-to-severe major depressive disorder (MDD). Benzinga · Aug 26, 2025
Benzinga · Aug 22, 2025 Tesla's Quality Score Tumbles, While Taiwan Semiconductor's Growth Rating Soars While daily stock price moves tend to dominate headlines, shifts in fundamental ranking scores can often tell a deeper story about a company's trajectory. This week, Benzinga's proprietary Growth, Value, Quality and Momentum data revealed major swings among household names, from electric vehicles to pharmaceuticals and financials.
Benzinga · Aug 21, 2025 AbbVie's Patch Baldness Study Finds High Hair Coverage Rates With Investigational Drug Upadacitinib AbbVie Inc. (NYSE:ABBV) on Thursday released topline results from the second of two pivotal studies of the Phase 3 UP-AA clinical program evaluating the safety and efficacy of upadacitinib (RINVOQ; 15 mg and 30 mg, once daily) in adult and adolescent patients with severe alopecia areata (AA) with a mean…
Reason · Aug 9, 2025 Sixth Circuit Rejects Associational Standing in Medicare Drug Pricing Challenge An easy way to avoid the merits in the latest high-stake health care litigation.
Benzinga · Aug 8, 2025 AbbVie Inclusion In Medicare Drug Talks Fails To Justify Lawsuit, Court Rules AbbVie Inc. (NYSE:ABBV), the manufacturer of Imbruvica, is at the center of a constitutional challenge to the federal government's new Drug Price Negotiation Program.
Barchart · Aug 5, 2025 AbbVie Stock Outlook: Is Wall Street Bullish or Bearish? Despite AbbVie’s underperformance relative to the S&P 500 over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.
Benzinga · Aug 1, 2025 AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion.
Benzinga · Aug 1, 2025 5 Dividend Stocks With Solid Returns And More Growth Ahead Sector by sector, U.S. dividend stocks have outperformed so far this year, with historically dividend-friendly industries surpassing those with a more growth-oriented focus.
MarketBeat · Jul 31, 2025 AbbVie Stock Eyes Breakout as Pipeline and Profits Grow AbbVie stock pops after strong Q2 earnings and raised guidance, as Skyrizi and Rinvoq offset Humira's decline and support a bullish outlook
Benzinga · Jul 31, 2025 AbbVie Lifts Outlook, Eyes Parkinson's Assets As Next Growth Frontier AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion. Sales increased 6.6% on a reported basis or 6.5% on an operational basis. The company reported adjusted earnings of $2.97, up 12.1% year over year and missing the consensus of $3.23.
Euronews · Jul 31, 2025 Seven all-American products that are actually 'Made in Europe', set to be hit by US tariffs Trump’s tariffs are aimed at ostensibly boosting US production and fostering a “local for locals” sensibility. Except, it turns out that several American product staples are actually... "Made in Europe"?
Benzinga · Jul 24, 2025 Uber, Western Union, Live Nation Entertainment And A Health Care Stock On CNBC's 'Final Trades' As investors navigate a volatile market landscape, attention turns to upcoming earnings reports from major companies, which could provide insights into broader economic trends. This earnings season, analysts and investors are closely watching key players like AbbVie, Uber, and Western Union for signs of growth and stability amid shifting market…